Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

[1]  S. Srivastava,et al.  Predominance of ERG-negative high-grade prostate cancers in African American men. , 2014, Molecular and clinical oncology.

[2]  M. Rubin,et al.  Antibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer , 2014, Molecular oncology.

[3]  S. Srivastava,et al.  ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. , 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[4]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[5]  Ronald J. Moore,et al.  Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. , 2013, Journal of proteome research.

[6]  S. Srivastava,et al.  Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India , 2013, Journal of Cancer.

[7]  C. Cooper,et al.  The Present and Future of Prostate Cancer Urine Biomarkers , 2013, International journal of molecular sciences.

[8]  A. Uren,et al.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. , 2013, American journal of translational research.

[9]  L. Cartegni,et al.  5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer , 2013, PloS one.

[10]  W. Qian,et al.  Antibody-free PRISM-SRM for multiplexed protein quantification: is this the new competition for immunoassays in bioanalysis? , 2013, Bioanalysis.

[11]  S. Srivastava,et al.  Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.

[12]  Ronald J. Moore,et al.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.

[13]  R. Aebersold,et al.  Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.

[14]  Richard D. Smith,et al.  Advancing the sensitivity of selected reaction monitoring‐based targeted quantitative proteomics , 2012, Proteomics.

[15]  John T. Wei,et al.  Beyond PSA: The Next Generation of Prostate Cancer Biomarkers , 2012, Science Translational Medicine.

[16]  G. Kristiansen,et al.  ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies , 2012, Prostate Cancer and Prostatic Diseases.

[17]  Arul M Chinnaiyan,et al.  Common gene rearrangements in prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Varambally,et al.  TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. , 2011, Cancer research.

[19]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[20]  L. Waldron,et al.  mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.

[21]  M. Rubin,et al.  TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.

[22]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[23]  D. Berney,et al.  Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.

[24]  S-H Tan,et al.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.

[25]  Brendan MacLean,et al.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments , 2010, Bioinform..

[26]  S. Booth,et al.  Quantitative Reverse-Transcription Polymerase Chain Reaction Analysis of Alzheimer's-Associated Genes in Mouse Scrapie , 2009, Journal of toxicology and environmental health. Part A.

[27]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[28]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[29]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[30]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[31]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[34]  D. Albertson,et al.  Chromosome aberrations in solid tumors , 2003, Nature Genetics.

[35]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[36]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[37]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[38]  V. Sementchenko,et al.  ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.

[39]  T. Papas,et al.  The erg gene: a human gene related to the ets oncogene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Papas,et al.  erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. , 1987, Science.